Bisphosphonate Remains Highly Localized After Elution From Porous Implants
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Local elution of zoledronic acid from a porous implant reportedly enhances periimplant bone formation and implant fixation. However, there is no information in the literature on the extent to which eluted bisphosphonate remains localized around the implant or becomes systemically distributed.
We ascertained to what extent eluted zoledronic acid remains local and whether there is systemic exposure after local elution from porous implants.
A hydroxyapatite-coated porous tantalum implant dosed with 100 μg 14C-labeled zoledronic acid was implanted into the left femoral intramedullary canal of six dogs. Bone samples near to and distant from the implant were harvested from three dogs at 6 weeks and three dogs at 52 weeks. The concentration of radiolabeled bisphosphonate in each sample was quantified using liquid scintillation spectrophotometry and its distribution in periimplant bone was revealed by exposing histologic sections to autoradiography film.
In all six dogs, the concentration of zoledronic acid in immediate periimplant bone was two orders of magnitude higher than in any other sampled tissue, averaging 732.6 ng/g at 6 weeks and 377.2 ng/g at 52 weeks. Minute amounts of zoledronic acid (≤ 7.2 ng/g) were detected throughout the skeleton, indicating some escape into the circulation after local elution. Autoradiographs revealed the greatest concentration of zoledronic acid on and within the implant, with rapid decrease short distances away and no uptake within the femoral cortex.
Zoledronic acid eluted from an implant remains mainly localized with minimal systemic distribution.
Local bisphosphonate elution reduces the risk of systemic side effects and skeletal bisphosphonate exposure.
- Allen, MR, Iwata, K, Phipps, R, Burr, DB (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 39: pp. 872-879 CrossRef
- Amanat, N, McDonald, M, Godfrey, C, Bilston, L, Little, D (2007) Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 22: pp. 867-876 CrossRef
- Åstrand, J, Aspenberg, P (2004) Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res. 22: pp. 244-249 CrossRef
- Black, DM, Delmas, PD, Eastell, R, Reid, IR, Boonen, S, Cauley, JA, Cosman, F, Lakatos, P, Leung, PC, Man, Z, Mautalen, C, Mesenbrink, P, Hu, H, Caminis, J, Tong, K, Rosario-Jansen, T, Krasnow, J, Hue, TF, Sellmeyer, D, Eriksen, EF, Cummings, SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 356: pp. 1809-1822 CrossRef
- Bobyn, JD, McKenzie, K, Karabasz, D, Krygier, JJ, Tanzer, M (2009) Locally delivered bisphosphonate for enhancement of bone formation and implant fixation. J Bone Joint Surg Am. 91: pp. 23-31 CrossRef
- Drake, MT, Clarke, BT, Khosla, S (2008) Bisphosphonates: mechanisms of action and role in clinical Practice. Mayo Clin Proc. 83: pp. 1032-1045 CrossRef
- Gao, Y, Zou, S, Liu, X, Bao, C, Hu, J (2009) The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials. 30: pp. 1790-1796 CrossRef
- Garbuz, DS, Hu, Y, Kim, WY, Duan, K, Masri, BA, Oxland, TR, Burt, H, Wang, R, Duncan, CP (2008) Enhanced gap filling and osteoconduction associated with alendronate-calcium phosphate-coated porous tantalum. J Bone Joint Surg Am. 90: pp. 1090-1100 CrossRef
- Goh, SK, Yang, KY, Koh, JS, Wong, MK, Chua, SY, Chua, DT, Howe, TS (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 89: pp. 349-353 CrossRef
- Hilding, M, Aspenberg, P (2007) Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses. A randomized, double-blind radiostereometric study of 50 patients. Acta Orthop 78: pp. 795-799 CrossRef
- Hilding, M, Ryd, L, Toksvig-Larsen, S, Aspenberg, P (2000) Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients. Acta Orthop Scand. 71: pp. 553-557 CrossRef
- Jakobsen, T, Baas, J, Kold, S, Bechtold, JE, Elmengaard, B, Soballe, K (2009) Local bisphosphonate treatment increases fixation of hydroxyapatite-coated implants inserted with bone compaction. J Orthop Res. 27: pp. 189-194 CrossRef
- Kwek, EB, Koh, JS, Howe, TS (2008) More on atypical fractures of the femoral diaphysis [Letter]. N Engl J Med. 359: pp. 316-318 CrossRef
- Legay, F, Gauron, S, Deckert, F, Gosset, G, Pfaar, U, Ravera, C, Wiegand, H, Schran, H (2002) Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate in human serum, plasma and urine. J Pharm Biomed Anal. 30: pp. 897-911 CrossRef
- Lenart, BA, Lorich, DG, Lane, JM (2008) Atypicial fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 358: pp. 1304-1306 CrossRef
- Lyles, KW, Colón-Emeric, CS, Magaziner, JS, Adachi, JD, Pieper, CF, Mautalen, C, Hyldstrup, L, Recknor, C, Nordsletten, L, Moore, KA, Lavecchia, C, Zhang, J, Mesenbrink, P, Hodgson, PK, Abrams, K, Orloff, JJ, Horowitz, Z, Eriksen, EF, Boonen, S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 357: pp. 1799-1809 CrossRef
- Mashiba, T, Hirano, T, Turner, CH, Forwood, MR, Johnston, CC, Burr, DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 15: pp. 613-620 CrossRef
- Mashiba, T, Turner, CH, Hirano, T, Forwood, MR, Johnston, CC, Burr, DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 28: pp. 524-531 CrossRef
- Papapetrou, PD (2009) Bisphosphonate-associated adverse events. Hormones. 8: pp. 96-110
- Peter, B, Gauthier, O, Laïb, S, Bujoli, B, Guicheux, J, Janvier, P, Lenthe, GH, Müller, R, Zambelli, PY, Bouler, JM, Pioletti, DP (2006) Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mat Res Part A. 76: pp. 133-143 CrossRef
- Peter, B, Pioletti, DP, Laïb, S, Bujoli, B, Pilet, P, Janvier, P, Guicheux, J, Zambelli, PY, Bouler, JM, Gauthier, O (2005) Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone. 36: pp. 52-60 CrossRef
- Russell, RG, Xia, Z, Dunford, JE, Oppermann, U, Kwaasi, A, Hulley, PA, Kavanagh, KL, Triffitt, JT, Lundy, MW, Phipps, RJ, Barnett, BL, Coxon, FP, Rogers, MJ, Watts, NB, Ebetino, FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci. 1117: pp. 209-257 CrossRef
- Saleh KJ, Mulhall KJ, Hofmann AA, Bolognesi MP, Laskin RS. Primary total knee arthroplasty outcomes. In: Barrack RL, Booth RE Jr, Lonner JH, McCarthy JC, Mont MA, Rubash HE, eds. Orthopaedic Knowledge Update 3 - Hip and Knee Reconstruction. Rosemont, IL: Amer Acad Orthop Surg; 2006:93–110.
- Sporer S, Paprosky WG, Berry DJ. Hip revision. In: Barrack RL, Booth RE Jr, Lonner JH, McCarthy JC, Mont MA, Rubash HE, eds. Orthopaedic Knowledge Update 3 - Hip and Knee Reconstruction. Rosemont, IL: Amer Acad Orthop Surg; 2006:457–474.
- Stadelmann, VA, Gauthier, O, Terrier, A, Bouler, JM, Pioletti, DP (2008) Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model: a pilot study. Eur Cell Mater. 16: pp. 10-16
- Suratwala, SJ, Cho, SK, Raalte, JJ, Park, SH, Seo, SW, Chang, SS, Gardner, TR, Lee, FY (2008) Enhancement of periprosthetic bone qwuality with topical hydroxyapatite-bisphosphonate composite. J Bone Joint Surg Am. 90: pp. 2189-2196 CrossRef
- Tanzer, M, Karabasz, D, Krygier, JJ, Cohen, R, Bobyn, JD (2005) Bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Relat Res. 441: pp. 30-39 CrossRef
- Yaffe, A, Binderman, I, Breuer, E, Pinto, T, Golomb, G (1999) Disposition of alendronate following local delivery in a rat jaw. J Periodontol. 70: pp. 893-895 CrossRef
- Bisphosphonate Remains Highly Localized After Elution From Porous Implants
Clinical Orthopaedics and Related Research®
Volume 469, Issue 2 , pp 514-522
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Jo Miller Orthopaedic Research Laboratory, Montreal General Hospital, Montreal, Canada
- 2. Division of Orthopaedics, McGill University, 1650 Cedar Avenue, Rm LS1-409, Montreal, QC, H3G1A4, Canada